当前位置:
X-MOL 学术
›
Nat. Biotechnol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Will inter partes review speed US generic drug entry?
Nature Biotechnology ( IF 46.9 ) Pub Date : 2017-12-08 , DOI: 10.1038/nbt.4036 Jonathan J Darrow , Reed F Beall , Aaron S Kesselheim
Nature Biotechnology ( IF 46.9 ) Pub Date : 2017-12-08 , DOI: 10.1038/nbt.4036 Jonathan J Darrow , Reed F Beall , Aaron S Kesselheim
Will inter partes review speed US generic drug entry?
中文翻译:
将当事人之间审查速美仿制药进入?
将当事人之间审查速美仿制药进入?
更新日期:2017-12-10
Will <i>inter partes</i> review speed US generic drug entry?, Published online: 08 December 2017; doi:10.1038/nbt.4036
A new extra-judicial pathway for challenging pharmaceutical patents has intensified patent challenges and helped to clear the way for earlier generic entry.中文翻译:
将当事人之间审查速美仿制药进入?
将当事人之间审查速美仿制药进入?
各方是否会审查美国仿制药进入的速度?在线发布:2017年12月8日;doi:10.1038 / nbt.4036
挑战药品专利的新司法外途径加剧了专利挑战,并为早期的仿制药进入市场扫清了道路。